PP
ALNY icon

PDT Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

PDT Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,484
Closed -$958K – 707
2024
Q3 		$958K Sell
3,484
-10,800
-76% -$2.81M 0.08% 374
2024
Q2 		$3.47M Buy
+14,284
New +$2.26M 0.33% 86
2024
Q1 		– Sell
-5,916
Closed -$1.13M – 621
2023
Q4 		$1.13M Sell
5,916
-8,551
-59% -$1.46M 0.13% 268
2023
Q3 		$2.56M Buy
+14,467
New +$2.76M 0.32% 91
2021
Q1 		– Sell
-8,800
Closed -$1.14M – 761
2020
Q4 		$1.14M Buy
+8,800
New +$1.18M 0.08% 303
2020
Q2 		– Sell
-68,313
Closed -$7.44M – 659
2020
Q1 		$7.44M Sell
68,313
-48,700
-42% -$5.62M 0.59% 50
2019
Q4 		$13.5M Sell
117,013
-5,100
-4% -$508K 0.83% 6
2019
Q3 		$9.82M Sell
122,113
-16,687
-12% -$1.32M 0.58% 38
2019
Q2 		$10.1M Buy
138,800
+63,722
+85% +$4.89M 0.6% 41
2019
Q1 		$7.02M Buy
+75,078
New +$6.28M 0.4% 92
2017
Q4 		– Sell
-237,626
Closed -$27.9M – 530
2017
Q3 		$27.9M Sell
237,626
-57,474
-19% -$4.91M 0.92% 3
2017
Q2 		$23.5M Buy
+295,100
New +$18.9M 0.95% 19
2014
Q1 		– Sell
-5,804
Closed -$373K – 1291
2013
Q4 		$373K Buy
+5,804
New +$346K 0.04% 486

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

PDT Partners's ALNY Position: Q4 2024 in Review

PDT Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 3,484 shares — an estimated $958K sold.

PDT Partners first reported a position in ALNY in Q4 2013 and held it in 13 quarters. The position peaked at $27.9M in Q3 2017. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • PDT Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 3,484 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $958K.
  • PDT Partners first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 13 quarters.
  • PDT Partners's Alnylam Pharmaceuticals position peaked at $27.9M in Q3 2017.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.